hexamethonium has been researched along with Growth Disorders in 1 studies
Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.
Growth Disorders: Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wilczynski, EA | 1 |
| Leenen, FH | 1 |
1 other study available for hexamethonium and Growth Disorders
| Article | Year |
|---|---|
Dietary sodium intake and age in spontaneously hypertensive rats: effects on blood pressure and sympathetic activity.
Topics: Aging; Animals; Blood Pressure; Body Weight; Catecholamines; Diet, Sodium-Restricted; Growth Disorde | 1987 |